Seth’s 50 State Network Advocate Brief: Prior Authorization
JUST IN
How Can You Help? Many states are currently introducing or revising legislation regarding prior authorization. Through your grassroots advocacy as part of the 50 State Network— online and in-person — the Prior Authorization message of poor outcomes, inefficiencies, and higher costs can be conveyed to: State elected officials and staffers (legislators and […]
How can you help? Help support bills that limit patients’ costs for specialty tier drugs. 87% of stand-alone Medicare Part D Prescription Drug Plans and 98% of Medicare Advantage-Prescription Drug Plans use specialty tiers, and this can be very expensive for those in need of special medicines. Patients who need non-preferred or specialty tier drugs […]
by Ben Nowell, MSW, Ph.D. Anyone in science or academia will tell you that the primary goal of undertaking a Ph.D. is to learn how to become a research scientist. Having recently completed a Ph.D. myself, I now feel more excited, yet more daunted than ever about scientific research and its implications. But what […]
The Global Healthy Living Foundation (GHLF) is excited to announce its support for the recent release of an Alliance for Integrity and Reform of 340B (AIR 340B) hospital charity care analysis entitled “Unfulfilled Expectations: An Analysis of Charity Care provided by 340B Hospitals”. Congress created the 340B program in 1992 to help uninsured, low-income patients […]
How can you help? Currently, state governments across the country are holding hearings to debate the introduction, modification, or total removal of Fail First/Step Therapy policies in their state. Through your grassroots advocacy as part of the 50 State Network— online and in-person — the Fail First message of poor outcomes, inefficiencies, and higher costs […]
On September 26th GHLF submitted a letter to Commissioner Hamburg at the FDA written by GHLF Chief Medical Officer, Dr. Jonathan Krant. The letter explains that biosimilars are not like generic drugs. A biosimilar product is highly similar to, but not the same as it’s reference biologic product. Therefore, from a patient safety perspective, it is […]
In March 2010, a U.S. biosimilar pathway was signed into law as part of the Affordable Care Act (ACA). In February 2012, the Food and Drug Administration (FDA) issued three draft guidance documents on biosimilar product development to assist industry in developing such products in the United States. What, if any, additional guidance FDA may issue, and when, is uncertain.